Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine - Wikidata - awgldk - TriplyDB

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

http://www.wikidata.org/entity/Q28390007

about

Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside Calcium phosphate nanoparticles-based systems for siRNA delivery Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma Lipid-Based Nanocarriers for RNA Delivery Technologies for controlled, local delivery of siRNA Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Light-mediated activation of siRNA Release in diblock copolymer assemblies for controlled gene silencing.Influence of cationic lipid concentration on properties of lipid-polymer hybrid nanospheres for gene delivery.Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response.The delivery of therapeutic oligonucleotides Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis.Polymer nanoassemblies with hydrophobic pendant groups in the core induce false positive siRNA transfection in luciferase reporter assays.Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA.Small Players Ruling the Hard Game: siRNA in Bone Regeneration.A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy.Facile Generation of Tumor-pH-Labile Linkage-Bridged Block Copolymers for Chemotherapeutic Delivery.Lipid-based nanovesicles for nanomedicine.Chitosan-coated red fluorescent protein nanoparticle as a potential dual-functional siRNA carrier.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Self-assembled DNA nanostructures prepared by rolling circle amplification for the delivery of siRNA conjugates.Nanomedicine applications in the treatment of breast cancer: current state of the art.Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo.Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines.Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities.Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.Diblock Copolymer Hydrophobicity Facilitates Efficient Gene Silencing and Cytocompatible Nanoparticle-Mediated siRNA Delivery to Musculoskeletal Cell Types.A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid.Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing.A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA.Twenty-five years of nano-bio-materials: have we revolutionized healthcare?Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis.Reducible Dimeric Conjugates of Small Internally Segment Interfering RNA for Efficient Gene Silencing.Light-triggered RNA release and induction of hMSC osteogenesis via photodegradable, dual-crosslinked hydrogels.Development of Controlled Drug Delivery Systems for Bone Fracture-Targeted Therapeutic Delivery: A Review.Effects of lipid composition on the properties of doxorubicin-loaded liposomes.Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus.Clustered Regularly Interspaced Short Palindromic Repeats-Based Genome Surgery for the Treatment of Autosomal Dominant Retinitis Pigmentosa.Non-Viral Based miR Delivery and Recent Developments.Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.

P2860

Q26741449-60EEE3E7-185A-4DAE-983B-15D2B28A2682 Q26744039-42C86648-ABE2-405D-98B1-53D38F9BC147 Q26744830-4DB0071B-0EAB-4EA7-AF92-A0FCCDEEA5E3 Q28080706-B656223A-5166-4C6E-8505-0A736F375BA8 Q28087657-3E4968A3-F5B0-4CCE-8FC4-97C5CA4EB125 Q33627888-07E63006-1A45-436D-9611-D79101C421F3 Q35131115-76CF303E-208B-44F1-8E38-8771090CA2C0 Q35598648-14438E85-1F58-4D35-B2C9-C4D5976FF19A Q36052188-91FE5E41-B574-40E0-9B8E-0AE602208A49 Q36293364-94782F43-5FBB-4E1B-80A4-EC1A0F9B5CC6 Q37210936-71861022-6B42-4CB0-B54B-ED2749BF6F8D Q37636279-AB54B180-D959-4D69-B637-B604C8BF4FD3 Q38699802-0B88E72B-93A6-4C67-9282-D7919B35C130 Q38710260-3A495D0A-D6FC-43F4-9706-EA6E90ED31A7 Q38738927-7EA6E01A-1034-4045-81EE-5A6DE89A527B Q38749605-7725F501-E940-4B67-8362-0B1454BEC202 Q38804608-9B777CF4-5365-4C68-B180-630D9E1D6AC8 Q38813182-BD892306-CF49-4A32-8F2B-A95A838156DB Q38857610-99C44E49-EF17-4A0D-951B-4307EA7186F1 Q38889573-5B846F1F-C535-4523-AA8B-7D211BC51FAA Q38981026-399B55EC-0C06-4F2E-A30D-3AD228ECF929 Q41483629-C6523867-97E4-4022-AB88-A9E389E74A33 Q41928019-5DEB9052-CA57-4376-8DD7-A0703A769F38 Q42015845-142DB852-BF36-4CFC-9BA8-9C9CC8C5DB9D Q42592314-5C780116-FFCE-4127-81CA-7E1511D09582 Q46242176-02956A41-5051-4654-9CF4-5E879C772F16 Q47148640-24512119-10D1-4ED9-80EE-0314A306C1D9 Q47162722-A9465FEF-5B4E-49AF-8762-82FADB32CA11 Q48030459-A1688669-46F6-4957-8F74-29792F194200 Q48092346-F275129A-CEC0-4797-9D9B-4E00C25DCD6D Q50519344-D25A1730-A1E4-4C45-866D-4E202CF706D6 Q51008485-CE5D7D33-4698-41D0-8722-3AAC172083FD Q51300691-0A791682-1454-4424-A959-7C7F64F40DA8 Q51309757-7F165560-9BDD-4F7B-B743-D34240DF9462 Q51748839-52BDE064-A1AA-48AC-9019-0DD5A60DBF76 Q52927166-551AC3A7-D8AB-4EEC-A9B6-DB9B0823B71A Q54207404-CE7925E9-E977-44FC-A4F9-E55DB1F1B6EE Q54212285-68E862EA-BA2B-462C-A1B3-810CA23D31FF Q54231141-734A77A0-051C-45B5-91A8-9A0FFB43E318 Q55379950-CC14AF8D-BF53-4467-86CC-252A94DD9564

P2860

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

http://www.wikidata.org/entity/Q28390007

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@ast

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@en

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@nl

type

label

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@ast

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@en

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@nl

prefLabel

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@ast

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@en

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@nl

P1433

Q28390007-4D1CBF34-AE18-4ED6-800D-601EB46611D3

P1476

Q28390007-31010CC2-BFB9-44FC-8235-15E1A2E23E70

P2093

Q28390007-356DB438-0755-4E47-8A81-CF1C71CC6F11

Q28390007-46C431A9-EC98-43C6-9644-532898083FA6

Q28390007-D620C5EA-7D86-4ABF-B53F-BB66F5C5A930

P2860

Q28390007-028BC654-0830-45F7-90AA-B31F3D5237EE

Q28390007-032615DC-061B-42A6-AF8D-D0E828B0E917

Q28390007-07288327-534E-4139-98ED-93279438B1AF

Q28390007-09AEAA2F-2172-46C7-B97D-021576802D72

Q28390007-0ADB8EA4-F1A9-4B2A-AC34-A270E5AF63E9

Q28390007-11A339C1-F1A7-43EA-B27E-B0D82582BE79

Q28390007-13769165-694B-4B20-9989-003A7E0F4F7F

Q28390007-15BDB4C4-3C1E-4AD7-A0D3-E350F1E923EC

Q28390007-1607990C-C3F7-4D84-BA97-9E970A377A72

Q28390007-169D83B8-D6A9-4BB7-85E3-939D3E04ACAB

P304

Q28390007-E5AC1FF0-29BF-4317-9EE1-6E1472A8097B

P31

Q28390007-B5DB85EF-5A16-48B5-80A4-38B63BE00378

P3181

Q28390007-242FA96D-A647-4E13-BDD3-B3D8181A1AE7

P356

Q28390007-390C03A4-0D8A-44C1-A215-5DA9A32DC7B9

P407

Q28390007-7B378D32-950F-481C-8347-BB1390270F2A

P433

Q28390007-5B1410F1-35BC-4000-A350-8ED8947EB5BC

P478

Q28390007-D2A15F34-8F87-4E3A-9963-C451AD65BB9E

P577

Q28390007-4CD85DAC-F756-45BB-A01B-2D5F757E6E6F

P698

Q28390007-71792406-E676-444C-A67D-44B696248D89

P932

Q28390007-EC2207CC-9891-424C-B46A-E11591161BBF

P3181

P356

P1433

P1476

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

@en

P2093

Ho Lun Wong

http://www.w3.org/2001/XMLSchema#string

Hui Yi Xue

http://www.w3.org/2001/XMLSchema#string

Shimeng Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappa B, and Akt in normal and malignant human mesothelial cells

Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure

Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition.

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area

Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study

Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity.

Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice.

P304

295-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

764751

http://www.w3.org/2001/XMLSchema#string

P356

10.2217/NNM.13.204

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24552562

http://www.w3.org/2001/XMLSchema#string

P932

4095781

http://www.w3.org/2001/XMLSchema#string